Skip to content
Open access

Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer

Aug 2026 · Cancer Genomics & Proteomics · Vol 23, pp. 1061 - 1081 · 0 citations · 46 references
Medicine

TL;DR

The routine implementation of comprehensive genomic profiling in metastatic HER2-negative breast cancer, especially in metastatic HER2-negative breast cancer, is supported to guide precision oncology strategies and enable enrollment in biomarker-driven clinical trials.

Abstract

Abstract Background/Aim: In breast cancer, knowledge of the associations between clinicopathologic characteristics, genetic changes, and subtype-specific patterns is expanding. This study investigated how pathological and clinical variables affect the actionability of Next Generation Sequencing (NGS)-based tumor molecular data. Materials and Methods: 227 breast cancer patients referred to Genekor’s laboratory for tumor molecular profile analysis were included in the study. Pathology records were used to assess critical clinicopathological features, including HER2, ER, PR, Ki67, grade, metastatic site, and age. A 1021-gene NGS-based multigene panel was utilized to assess tumor biology alongside tumor mutational burden (TMB) and microsatellite instability (MSI). Results: Comprehensive genomic profiling revealed that 95.6% of the patients harbored at least one oncogenic or likely oncogenic alteration, highlighting the high diagnostic yield of NGS-based testing. Distinct subtype-specific patterns were observed: HR+/HER2- tumors were enriched for PIK3CA and ESR1 gene alterations, whereas triple-negative breast cancer (TNBC) was dominated by TP53 alterations. Clinically actionable alterations were most common in HR+/HER2- tumors (~60% on-label), whereas TNBC more often harbored off-label or trial-associated targets. The inclusion of tumor-agnostic biomarkers (TMB/MSI) increased on-label actionability up to 64.5% in HR+/HER2− tumors, primarily driven by TMB-high cases. Median TMB values were low, and age was the only independent predictor. Furthermore, the presence of actionable alterations was significantly higher in metastatic tumors, and TP53 alterations were associated with aggressive tumor characteristics. Conclusion: Comprehensive NGS-based genomic profiling identifies clinically actionable alterations in over half of breast cancer patients, with substantial variability across molecular subtypes. The HR+/HER2- subtype demonstrates the highest prevalence of on-label actionable biomarkers. These findings support the routine implementation of comprehensive genomic profiling, especially in metastatic HER2-negative breast cancer, to guide precision oncology strategies and enable enrollment in biomarker-driven clinical trials.

Read PDF

Similar papers

Open access Sep 2026

Tumor genomic landscape of older patients with metastatic breast cancer☆

Background Metastatic breast cancer (MBC) in older patients has distinct clinical and histologic characteristics. Elucidating the genomic basis of MBC helps identify potential therapeutic targets to improve outcomes for older patients with MBC. Patients and methods Using a prospective database and targeted DNA sequenci...

H. Gupta, K. Brantley, T. Grinda et al. · 0 citations
Open access Aug 2026

Integrated Molecular Profiling of Endometrial Cancer: NGS Findings, MSI/MMR Status, Histopathological Features, and TCGA-Inspired Molecular Classification

Background/Objectives: Endometrial cancer is a heterogeneous malignancy that displays distinct molecular features and clinical behaviors. The molecular profile of endometrial cancer and its relationship with menopausal status, histological subtype, tumor grade, mismatch repair (MMR)/microsatellite instability (MSI) sta...

Merve Cirak-Balta, S. Erdoğdu, Büşra Ekinci et al. · 0 citations
Open access Aug 2026

Decoding age-stratified clinical and molecular heterogeneity in male breast cancer through multiomic profiling.

Objective Age-associated molecular heterogeneity is well described in female breast cancer but remains insufficiently characterized in male breast cancer (MBC). We profiled age-stratified clinical and molecular differences between younger (≤55 years) male breast cancer (YMBC) and older (>55 years) male breast cancer (O...

Zhi-Shuang Gao, Ze-Hao Wang, Yue Zhou et al. · 0 citations
Open access Oct 2026

TP53 Genomic Alterations Including Targetable Y220C Mutation in Advanced Breast Cancer

TP53 Y220C is a rare genomic alteration (GA) with emerging targeted therapies. However, its prevalence in breast cancer remains undefined. We evaluated the prevalence of the Y220C alteration and association with other GAs. A total of 23,760 patients with advanced breast cancer were analyzed by hybrid ca...

N. Casasanta, Adriana M. Kahn, N. Fischbach et al. · 0 citations
Open access Sep 2026

Tumor genomic alterations and their exploratory association with treatment response in recurrent head and neck cancer patients

While the genetic landscape of treatment-naïve head and neck squamous cell carcinoma (HNSCC) is well characterized, the molecular features of recurrent disease remain less defined. We investigated the genetic alterations in recurrent HNSCC and their associations with overall survival (OS), progression-free survival...

Olive Beyer, Andrey Loginov, D. Arons et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.